Clinical trials: COVID
SARS-CoV-2 Infection, COVID-19
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 (molnupiravir) versus placebo as measured by SARS-CoV-2 viral RNA…
- Trial name
- NCT04405570
- Testing
- Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg
- Where
- 10 sites in United States
- Volunteers
- 204 people
- Sponsor
- Ridgeback Biotherapeutics, LP
COVID-19, SARS-CoV-2
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
- Trial name
- NCT04516746
- Testing
- AZD1222
- Where
- 84 sites in United States, Chile and 1 more
- Volunteers
- 32,450 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
SARS-CoV-2
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04470427
- Testing
- mRNA-1273
- Where
- 100 sites in United States
- Volunteers
- 30,415 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 Infection, Acute Kidney Injury
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+)…
- Trial name
- NIRVANA (NCT04818216)
- Testing
- Nicotinamide riboside
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Covid19
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
This study looks at the safety and effectiveness of Aviptadil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- NCT06729606
- Testing
- Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 471 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, SARS-CoV Infection
SARS-CoV-2 Human Challenge Characterisation Study
This is a dose optimisation study in healthy adults aged 18-30 who will be experimentally inoculated with SARS-CoV-2. The aim is to cause PCR-confirmed upper respiratory infection in the majority of challenged individuals with…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection, Coronavirus
- Trial name
- NCT04865237
- Testing
- SARS-CoV-2 Virus 1x10^1 TCID50, Remdesivir, SARS-CoV-2 Virus 1x10^2 TCID50
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COVID-19, Venous Thromboses
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the…
- Conditions
- COVID-19, Venous Thromboses, Arterial Thrombosis
- Trial name
- IMPROVE (NCT04367831)
- Testing
- Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Columbia University
Severe Acute Respiratory Syndrome, Ventilation Pneumonitis
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.
- Trial name
- IDEA (NCT04425863)
- Testing
- Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets, Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets, Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.
- Where
- Argentina
- Volunteers
- 167 people
- Sponsor
- Eurnekian Public Hospital
Covid19, SARS-CoV-2 PNEUMONIA
Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Coronavirus is an acute viral disease with prevailing upper respiratory tract infections caused by the RNA-containing virus of the genus Betacoronavirus of the Coronaviridae family.
- Conditions
- Covid19, SARS-CoV-2 PNEUMONIA, COVID-19
- Trial name
- COVID-19EXO (NCT04491240)
- Testing
- EXO 1 inhalation, EXO 2 inhalation
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- State-Financed Health Facility "Samara Regional Medical Center Dinasty"
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
Post COVID-19 Condition, Long COVID
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
- Trial name
- NCT05592418
- Testing
- Rintatolimod
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- AIM ImmunoTech Inc.
SARS-CoV-2, COVID-19 Vaccines
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall…
- Trial name
- NCT06199934
- Testing
- Vaccination
- Where
- United States
- Volunteers
- 19,853,610 people
- Sponsor
- Pfizer
COVID 19
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using combinations of approved and safe repurposed interventions, with complementary mechanisms of action.
- Trial name
- CROWN CORONA (NCT04333732)
- Testing
- MR or M-M-R II ® vaccine
- Where
- 17 sites in United States, Ghana and 3 more
- Volunteers
- 3,411 people
- Sponsor
- Washington University School of Medicine
Covid19
ACTIV-6: COVID-19 Study of Repurposed Medications
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
- Trial name
- NCT04885530
- Testing
- Ivermectin, Fluvoxamine, Fluticasone
- Where
- 110 sites in United States
- Volunteers
- 10,956 people
- Sponsor
- Susanna Naggie, MD
COVID-19, SARS-CoV 2
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest…
- Conditions
- COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease
- Trial name
- AMPoL (NCT04409873)
- Testing
- Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, San Francisco
SARS-CoV-2
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an…
- Trial name
- NCT04796896
- Testing
- mRNA-1273, mRNA-1273.214
- Where
- 91 sites in United States, Canada
- Volunteers
- 11,942 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Biological Availability, Healthy Participants
Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult…
- Trial name
- NCT05525910
- Testing
- Nirmatrelvir/ ritonavir, Nirmatrelvir/ritonavir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, SARS-CoV-2
Study of Sargramostim in Patients With COVID-19
The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19.
- Trial name
- iLeukPulm (NCT04411680)
- Testing
- Sargramostim, Standard of care
- Where
- 11 sites in United States
- Volunteers
- 123 people
- Sponsor
- Partner Therapeutics, Inc.
COVID-19
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
- Trial name
- NCT04354831
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Medical College of Wisconsin
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.